首页> 美国卫生研究院文献>Cancer Science >Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation
【2h】

Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation

机译:新型抑制E-box结合的吡咯-咪唑聚酰胺抑制MYC驱动的细胞增殖的鉴定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The MYC transcription factor plays a crucial role in the regulation of cell cycle progression, apoptosis, angiogenesis, and cellular transformation. Due to its oncogenic activities and overexpression in a majority of human cancers, it is an interesting target for novel drug therapies. MYC binding to the E-box (5′-CACGTGT-3′) sequence at gene promoters contributes to more than 4000 MYC-dependent transcripts. Owing to its importance in MYC regulation, we designed a novel sequence-specific DNA-binding pyrrole–imidazole (PI) polyamide, Myc-5, that recognizes the E-box consensus sequence. Bioinformatics analysis revealed that the Myc-5 binding sequence appeared in 5′- MYC binding E-box sequences at the eIF4G1, CCND1, and CDK4 gene promoters. Furthermore, ChIP coupled with detection by quantitative PCR indicated that Myc-5 has the ability to inhibit MYC binding at the target gene promoters and thus cause downregulation at the mRNA level and protein expression of its target genes in human Burkitt's lymphoma model cell line, P493.6, carrying an inducible MYC repression system and the K562 (human chronic myelogenous leukemia) cell line. Single i.v. injection of Myc-5 at 7.5 mg/kg dose caused significant tumor growth inhibition in a MYC-dependent tumor xenograft model without evidence of toxicity. We report here a compelling rationale for the identification of a PI polyamide that inhibits a part of E-box-mediated MYC downstream gene expression and is a model for showing that phenotype-associated MYC downstream gene targets consequently inhibit MYC-dependent tumor growth.
机译:MYC转录因子在调节细胞周期进程,凋亡,血管生成和细胞转化中起着至关重要的作用。由于其致癌活性和在大多数人类癌症中的过度表达,它是新型药物疗法的有趣靶标。 MYC在基因启动子上与E-box(5'-CACGTGT-3')序列的结合有助于产生超过4000种依赖MYC的转录本。由于其在MYC调控中的重要性,我们设计了一种新型的具有序列特异性的结合DNA的吡咯-咪唑(PI)聚酰胺Myc-5,它可以识别E-box共有序列。生物信息学分析表明,Myc-5结合序列出现在eIF4G1,CCND1和CDK4基因启动子的5'-MYC结合E-box序列中。此外,ChIP结合定量PCR检测表明,Myc-5具有抑制MYC与靶基因启动子结合的能力,从而在人伯基特淋巴瘤模型细胞系P493中引起其靶基因的mRNA水平和蛋白表达下调。 .6,带有可诱导的MYC抑制系统和K562(人类慢性骨髓性白血病)细胞系。单曲在依赖MYC的肿瘤异种移植模型中,以7.5 mg / kg的剂量注射Myc-5导致显着的肿瘤生长抑制,而没有毒性的证据。我们在这里报告一个令人信服的理由,以鉴定抑制聚酰胺的一部分E框介导的MYC下游基因表达的PI聚酰胺,并且是一个模型,用于显示与表型相关的MYC下游基因目标因此抑制MYC依赖的肿瘤生长。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号